Terumo offers safe and effective treatment for resistant hypertension
Terumo Europe has announced that it will showcase its Iberis™ Renal Sympathetic Denervation System at the RHC (Resistant Hypertension Course) in Berlin (20-22 February 2014).
The Iberis™ System offers interventional treatment to patients with high blood pressure who poorly respond to conventional medication therapy.
It will be exhibited at the RHC in Berlin – a joint initiative of the European Association of Percutaneous Cardiovascular Intervention, European Society of Hypertension, and PCR Organisation – which aims to provide a forum for healthcare experts Terumo Europe Interventional Systems’ President Peter Coenen said:
“Terumo has a long history of being at the forefront of medical devices that benefit healthcare providers and patients alike. The Iberis™ System demonstrates that Terumo continues to be at the cutting edge of developing the next generation of technology to deliver excellence in patient care. The Resistant Hypertension Course in Berlin is the perfect forum to demonstrate how the Iberis™ System can deliver safe and effective treatment for patients, and to explore how the technology can continue to be expanded and refined through ongoing clinical programs.”
In addition to the RHC in Berlin, Terumo has recently exhibited the Iberis™ System at the TRENDS 2014 meeting held in Germany and the JIM (Joint Interventional Meeting) in Rome recently, and will appear at further scientific courses throughout the year.
The renal sympathetic nerve plexus is a major contributor of hypertension. During renal sympathetic denervation, a catheter is introduced using standard interventional technique via the femoral artery, and is positioned in the renal artery under fluoroscopic guidance. The electrode at the distal tip of the catheter delivers high radio frequency through the wall of the renal artery to ablate or disrupt the surrounding renal sympathetic nerves lying in the vessel. Renal sympathetic denervation using a catheter-based technique is highly expected to be a new, effective treatment option for many patients with hypertension who do not respond to conventional drugs, or "resistant hypertension".
The Iberis™ system, which was granted CE certification in April 2013, is a catheter delivering high radio frequency energy through the wall of the renal artery to ablate or disrupt the surrounding renal sympathetic nerves. The Iberis™ System is available in a design for femoral access as well as the minimally invasive design for radial access.
Tokyo-based Terumo Corporation is one of the world’s leading medical device manufacturers with € 3.5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use.
Terumo contributes to society by providing valued products and services to the healthcare market and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation’s shares are listed on the first section of the Tokyo Stock Exchange and is a component of the Nikkei, Japan’s leading stock index.
For more information about the Iberis™ system, visit : http://www.terumo-europe.com/cardiology/products/iberis-renal-sympathetic-denervation-system.php
Contact: Mr. Olivier Archer, Terumo Europe N.V., +33 1 39 30 47 53 Olivier.Archer@terumo-europe.com